Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of human group 6A iPLA2 using PAPC as substrate preincubated for 5 mins with substrate followed by enzyme addition for 30 mins by mixed micelle-based assay
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human group 6A iPLA2 using PAPC/[14C]-labeled PAPC as substrate after 30 mins by mixed micelle-based assay
Assay data:2 Tested
Inhibition of human group 6A iPLA2 using PAPC/[14C]-labeled PAPC as substrate at 0.091 mole fraction after 30 mins by mixed micelle-based assay relative to control
Assay data:10 Tested
Competitive-reversible inhibition of N-terminal 6xHis-tag human group VIA calcium-independent PLA2 expressed in fall armyworm sf9 cells using PAPC/arachidonyl-1-14C PAPC as substrate by mixed micelle modified Dole assay
Binding affinity to Group VIA calcium-independent PLA2 (unknown origin) (770 to 778 residues) assessed as change in average deuteration level preincubated for 30 mins followed by D2O addition measured after 10 to 10000 secs by DXMS analysis
Binding affinity to Group VIA calcium-independent PLA2 (unknown origin) (718 to 730 residues) assessed as change in average deuteration level preincubated for 30 mins followed by D2O addition measured after 10 to 10000 secs by DXMS analysis
Binding affinity to Group VIA calcium-independent PLA2 (unknown origin) (656 to 664 residues) assessed as change in average deuteration level preincubated for 30 mins followed by D2O addition measured after 10 to 10000 secs by DXMS analysis
Binding affinity to Group VIA calcium-independent PLA2 (unknown origin) (630 to 655 residues) assessed as change in average deuteration level preincubated for 30 mins followed by D2O addition measured after 10 to 10000 secs by DXMS analysis
Binding affinity to Group VIA calcium-independent PLA2 (unknown origin) (542 to 562 residues) assessed as change in average deuteration level preincubated for 30 mins followed by D2O addition measured after 10 to 10000 secs by DXMS analysis
Binding affinity to Group VIA calcium-independent PLA2 (unknown origin) (514 to 524 residues) assessed as change in average deuteration level preincubated for 30 mins followed by D2O addition measured after 10 to 10000 secs by DXMS analysis
Binding affinity to Group VIA calcium-independent PLA2 (unknown origin) (481 to 493 residues) assessed as change in average deuteration level preincubated for 30 mins followed by D2O addition measured after 10 to 10000 secs by DXMS analysis
Inhibition of N-terminal 6xHis-tag human group VIA calcium-independent PLA2 expressed in fall armyworm sf9 cells at 0.091 mol fraction using PAPC/arachidonyl-1-14C PAPC as substrate by mixed micelle modified Dole assay
Assay data:26 Tested
Inhibition of N-terminal 6xHis-tag human group VIA calcium-independent PLA2 expressed in fall armyworm sf9 cells using PAPC/arachidonyl-1-14C PAPC as substrate by mixed micelle modified Dole assay
Assay data:13 Tested
Inhibition of human recombinant calcium-independent PLA2 using PAPA as substrate assessed as reduction in free FA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human recombinant iPLA2 assessed as reduction in free FA formation after 30 mins by HPLC-MS analysis
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human recombinant calcium-independent PLA2 using PAPE as substrate assessed as reduction in 16:0 LPE formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Assay data:2 Active, 1 Activity ≤ 1 nM, 2 Activity ≤ 1 µM, 2 Tested
Inhibition of human recombinant calcium-independent PLA2 using PAPC as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant calcium-independent PLA2 using PAPA as substrate assessed as reduction in 16:0 LPA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Assay data:2 Active, 2 Activity ≤ 1 nM, 2 Activity ≤ 1 µM, 2 Tested
Inhibition of human recombinant calcium-independent PLA2 using PAPG as substrate assessed as reduction in 16:0 LPG formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant calcium-independent PLA2 using PAPG as substrate assessed as reduction in free [14C]-AA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on